Online Exclusives

Online Exclusives

FDA Halts Phase I Trials of Vadastuximab Talirine in AML

The U.S. Food and Drug Administration (FDA) has placed clinical holds on several phase I trials of vadastuximab talirine (SGN-CD33A) in patients with acute...

Upfront Out-of-Pocket Costs for Expensive TKIs Could Cause Medicare Beneficiaries With Chronic Myeloid Leukemia...

A study published in the Journal of Clinical Oncology found that Medicare beneficiaries with chronic myeloid leukemia (CML) who incurred significant upfront out-of-pocket costs...

Study Links Multiple Myeloma to Obesity

A study published in the New England Journal of Medicine links obesity with 13 cancers, including multiple myeloma (MM). The study was conducted by...

Conference Coverage: Study Finds Clinical Benefit for RBC-Encapsulated Asparaginase in ALL

CHICAGO—Asparaginase is a commonly-prescribed treatment option for acute lymphocytic leukemia (ALL), but its use can be limited by its toxicities, including drug hypersensitivity. A...

Ibrutinib Submitted to FDA for Treatment of Marginal Zone Lymphoma

The U.S. Food and Drug Administration received a new drug application (NDA) for ibrutinib for the treatment of marginal zone lymphoma (MZL). If approved,...

FDA Grants Breakthrough Therapy Designation for Daratumumab Combinations for the Treatment of Multiple Myeloma

The U.S. Food and Drug Administration (FDA) granted breakthrough therapy designation for daratumumab in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone for...

FDA Grants Breakthrough Therapy Designation for Gene Therapy for Hemophilia B

The U.S. Food and Drug Administration (FDA) granted breakthrough therapy designation for the investigational gene therapy AMT-060 for severe hemophilia B. The FDA’s decision was...

Researchers Develop a New Agent for Hemophilia A

Researchers have developed a new bypassing agent that mimics the pro-clotting activity of factor V Leiden and gives the clotting process more time to...

ASH Joins Other Medical Organizations in Statement on Immigration Executive Order

In a joint statement, the American Society of Hematology, the American Association for Cancer Research, the Association of American Cancer Institutes, the American Society...

Generic Imatinib as Cost-Effective as First-Line Treatment for CML

This year, generic imatinib will be introduced in the United States and Europe and, according to a study published in the Journal of the...
Advertisement

Current Issue

August 2019, Volume 5, Issue 10

August 2019, Volume 5, Issue 10

This issue features a debate about gun control as a health care issue, a look at blood services in Israel and Palestine, and more.